New COVID Vaccine Codes

What are the new vaccine codes?

There are seven new procedure codes: 

XW013V7

– Introduction of COVID-19 vaccine dose 3 into subcutaneous tissue, percutaneous approach, new technology group 7

XW013W7

– Introduction of COVID-19 vaccine booster into subcutaneous tissue, percutaneous approach, new technology group 7

XW023V7

– Introduction of COVID-19 vaccine dose 3 into muscle, percutaneous approach, new technology group 7

XW023W7

– Introduction of COVID-19 vaccine booster into muscle, percutaneous approach, new technology group 7

XW0DXR7

– Introduction of fostamatinib into mouth and pharynx, external approach, new technology group 7

XW0G7R7

– Introduction of fostamatinib into upper GI, via natural or artificial opening, new technology group 7

XW0H7R7

– Introduction of fostamatinib into lower GI, via natural or artificial opening, new technology group 7

Fostamatinib is used to treat thrombocytopenia (less than normal number of platelets) in adults with chronic immune thrombocytopenia (ITP; an ongoing condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood) who were not helped with another treatment.  Fostamatinib significantly reduced serious adverse effects and risk of death in hospitalized COVID-19 patients, shows Phase II study.

In addition, three new diagnosis codes are being implemented into ICD-10-CM for reporting COVID-19 vaccination status, again effective April 1, 2022.

Those three new codes are:

Z28.310

– Unvaccinated for COVID-19

Z28.311

– Partially vaccinated for COVID-19

Z28.39

– Other under immunization status

The full updates for released ICD-10 MS-DRGs effective April 1,2022, can be found on the CMS website below.

References
https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software
https://www.aha.org/news/headline/2021-11-15-agencies-announce-new-icd-10-codes-reporting-covid-19-therapeutics
https://www.europeanpharmaceuticalreview.com/news/161903/fostamatinib-reduces-covid-19-risks-by-50-percent-in-phase-ii-study/

The information contained in this post is valid at the time of posting. Viewers are encouraged to research subsequent official guidance in the areas associated with the topic as they can change rapidly.